SEC takes enforcement action against 23 companies for claims relating to COVID-19.
Aint Nothing but a Gangter Party.
Like cryptocurrency and cannabis, the coronavirus pandemic may attract fraudsters keen to profit...
Biotech Stock Review: Mitesco (MITI) $0.03, Report Update
Mitesco to Launch Telehealth Enabled Primary Care Clinic Business with Q4 Rollout Addressing Healthcare Backlog Accentuated by the Second Wave Concerns.
Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double in 2020.
No Doubles Yet, But They're Doing Rather Well, Considering Everything. Our Confidence Remains Unwavered. Best Performer up 63%.
Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...
Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).
Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
True Nature | Mitesco (MITI) Raising $15 Million.
LIVE CHART
Mitesco, Inc. Announces up to $15 Million Unit Preferred Capital...
Immunomedics (IMMU) up 100% Today or $2 Billion in Value.
Again as mentioned a few weeks ago, our bearish market opinion is related to large-caps and large-cap funds and ETF's. If...
European Hand Sanitizer Market Expected to Reach $9.4 Billion by 2027.
Growing at a CAGR of 38.4% during 2019–2027.
The European hand sanitizer market was valued at US$ 641.7 million...
Revive Therapeutics Announces Entry Into Phase III FDA Trial Using Glutathione Boosting Bucillamine.
Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
TORONTO, April...
Antibiotic-Resistant Super Gonorrhea (CDC).
"We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common...
Is Overuse of Antibiotics on Farms Worsening the Spread of Antibiotic-Resistant Bacteria? (CBSNews)
Public health officials investigating a drug-resistant salmonella outbreak in 2015 still don't know the exact source after a pork-industry lobbying group on...
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
